COVAXIN to launch first indigenous corona vaccine in the country on August 15

Aiming to launch the country’s first indigenous COVID-19 vaccine by 15 August, the Indian Council of Medical Research (ICMR) has called for expediting the trial of Kovaxin, a vaccine to be developed in collaboration with Bharat Biotech. The Indian Council of Medical Research (ICMR) has written a letter to Bharat Biotech asking it to run Human Trial on Fast Track mode. ICMR has said that Bharat Biotech’s test results on corona vaccine humans may be released by August 15. This means that the country’s first indigenous corona vaccine (COVAXIN) may be launched by 15 August.

ICMR has written a letter to India’s leading vaccine manufacturer Bharat Biotech, which has developed an effective vaccine (COVAXIN) on Corona, to complete the human testing process of COVID19 vaccine using the Fast Track method. ICMR DG Balaram Bhargava has written a letter to the principal investigators of Bharat Biotech and Medical Colleges to expedite the testing process of the indigenous corona vaccine. This paper states that the process of human testing should be completed before August 15 so that clinical trial results can be launched by August 15. After this, on August 15, the first Corona vaccine made in the country ‘COVAXIN’ (COVAXIN) can be launched.

Preparations to accelerate vaccine trials

The letter states that it is the first indigenous vaccine being developed by India and is one of the highest priority projects being monitored at the highest level of government. Explain that ICMR has selected 12 institutes for trials on the country’s first indigenous Covid-19 vaccine humans.

Bhargava has written in his letter that after completion of all clinical trials, there is a plan to launch this vaccine for the common people by 15 August. India is working steadily to meet the biotech goal, however, the end result will depend on the cooperation of all clinical trial sites involved in the project. You have been selected as the clinical test site for the BBV152 COVID vaccine. In the wake of the COVID-19 epidemic and the urgency to launch the vaccine, you are advised to fast-track all clinical trial-related intervals in the wake of a public health emergency. All of you ensure that the trials begin on July 7.

Earlier, a letter written by ICMR DG to Bharat Biotech was leaked, in which the vaccine was said to be ready by August 15. The letter stated that by 15 August the vaccine would require more time for public use. The letter states that please note that non-compliance will be viewed very seriously, so you are advised to make this project a top priority and complete it on the given deadline without any lapse.

12 institutes selected for trial in the country

The Indian Council of Medical Research, ie ICMR, has selected 12 institutes for trials on the country’s first indigenous Covid-19 vaccine humans. One of these institutions is located in Odisha while the others are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulatur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.

India’s first indigenous vaccine (COVAXIN)

Recently, India’s leading vaccine manufacturer Bharat Biotech announced that it has made an effective vaccine (COVAXIN) against Corona. Not only this, but ICMR has also approved Bharat Biotech Phase I and II of human trials. Bharat Biotech said in its official statement that it has prepared the vaccine in collaboration with Indian Council of Medical Research, ie ICMR and National Institute of Virology (NIV).

India’s second corona vaccine is also ready

After Bharat Biotech’s (COVAXIN), Hyderabad-based pharmaceutical company Zydus Cadila Healthcare Ltd. Has also talked about making Covid-19 vaccine. Not only this, the Drug Controller General of India, DCGI has also approved the trial of Zydus Cadila on humans of this vaccine. With this, Zydus Cadila has become the second company in the country to get permission for tests on humans. Recently, Bharat Biotech of Hyderabad was allowed such trials


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *